Citigroup’s Immunomedics Inc IMMU Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2020
Q4
Sell
-145,800
Closed -$12.4M 7804
2020
Q3
$12.4M Buy
145,800
+7,800
+6% +$394K 0.01% 1207
2020
Q2
$4.89M Buy
138,000
+51,300
+59% +$1.5M ﹤0.01% 1879
2020
Q1
$1.17M Sell
86,700
-41,800
-33% -$703K ﹤0.01% 3007
2019
Q4
$2.72M Buy
128,500
+32,700
+34% +$577K ﹤0.01% 2664
2019
Q3
$1.27M Buy
95,800
+8,200
+9% +$121K ﹤0.01% 3367
2019
Q2
$1.22M Buy
87,600
+11,900
+16% +$179K ﹤0.01% 3403
2019
Q1
$1.45M Buy
75,700
+12,400
+20% +$200K ﹤0.01% 2997
2018
Q4
$903K Buy
63,300
+5,300
+9% +$105K ﹤0.01% 3506
2018
Q3
$1.21M Sell
58,000
-2,800
-5% -$66.3K ﹤0.01% 3277
2018
Q2
$1.44M Buy
60,800
+32,800
+117% +$659K ﹤0.01% 2995
2018
Q1
$409K Sell
28,000
-154,200
-85% -$2.52M ﹤0.01% 4208
2017
Q4
$2.94M Buy
182,200
+15,200
+9% +$179K ﹤0.01% 2304
2017
Q3
$2.33M Sell
167,000
-6,400
-4% -$63.8K ﹤0.01% 2494
2017
Q2
$1.53M Buy
173,400
+79,600
+85% +$559K ﹤0.01% 2857
2017
Q1
$607K Sell
93,800
-118,400
-56% -$600K ﹤0.01% 3700
2016
Q4
$779K Buy
212,200
+202,400
+2,065% +$599K ﹤0.01% 3941
2016
Q3
$32K Buy
9,800
+1,200
+14% +$3.36K ﹤0.01% 5948
2016
Q2
$20K Sell
8,600
-18,700
-68% -$62.5K ﹤0.01% 6175
2016
Q1
$68K Buy
27,300
+26,800
+5,360% +$60.3K ﹤0.01% 5933
2015
Q4
$2K Sell
500
-10,900
-96% -$30.4K ﹤0.01% 7309
2015
Q3
$20K Buy
11,400
+3,000
+36% +$7.66K ﹤0.01% 6045
2015
Q2
$34K Buy
+8,400
New +$34.3K ﹤0.01% 5791

Citigroup's IMMU Position: Q4 2020 in Review

Citigroup sold out of Immunomedics Inc (IMMU) in Q4 2020, closing a stake of 568,440 shares — an estimated $48.3M sold.

Citigroup first reported a position in IMMU in Q2 2013 and held it in 30 quarters. The position peaked at $48.3M in Q3 2020. 0 funds tracked by Wall St. Rank hold IMMU as of Q4 2020.

  • Citigroup reported no remaining Immunomedics Inc position as of Q4 2020 after selling out during the quarter.
  • Citigroup sold 568,440 Immunomedics Inc shares in Q4 2020, an estimated $48.3M.
  • Citigroup first reported a position in Immunomedics Inc in Q2 2013 and held it in 30 quarters.
  • Citigroup's Immunomedics Inc position peaked at $48.3M in Q3 2020.
  • 0 funds tracked by Wall St. Rank held Immunomedics Inc as of Q4 2020.

Based on Citigroup's 13F filing for Q4 2020, filed 11 Feb 2021.